Study Of SU011248 In Combination With Docetaxel And Trastuzumab In Patients With Advanced Breast Cancer HER-2 Positive

• Status: Completed
• Trial end date: 2011-09-01
• Target enrollment: 0
• Participant gender: Female

Summary

This is an exploratory trial evaluating the tolerability and preliminary anti-tumor activity of SU011248 combined with docetaxel and trastuzumab in patients with locally recurrent or metastatic breast cancer over-expressing Her-2, who have not received chemotherapy treatment in the advanced disease setting.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Docetaxel; Sunitinib; Trastuzumab

Criteria

Inclusion Criteria:

• Breast cancer with evidence of unresectable, locally recurrent, or metastatic disease.

• Tumors over-expressing Her-2

• Candidate for treatment with docetaxel/trastuzumab

Exclusion Criteria:

• Histology of inflammatory carcinoma

• AST and/or ALT >1.5 x ULN concomitant with ALP >2.5 x ULN